VIRGINIA RETIREMENT SYSTEMS ET Al Invests $41.45 Million in Neurocrine Biosciences, Inc. $NBIX

Posted by Brenda Bartman on Sep 7th, 2026

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The fund purchased 245,923 shares of the company’s stock, valued at approximately $41,447,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of NBIX. Geneos Wealth Management Inc. boosted its holdings in Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the last quarter. DJE Kapital AG acquired a new position in shares of Neurocrine Biosciences during the fourth quarter valued at approximately $28,000. Basecamp Wealth Advisors LLC lifted its position in shares of Neurocrine Biosciences by 582.9% in the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock valued at $31,000 after acquiring an additional 204 shares in the last quarter. Cassaday & Co Wealth Management LLC purchased a new position in shares of Neurocrine Biosciences in the first quarter valued at approximately $33,000. Finally, Meeder Asset Management Inc. lifted its position in shares of Neurocrine Biosciences by 651.6% in the fourth quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock valued at $33,000 after acquiring an additional 202 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Price Performance

Shares of NBIX stock opened at $155.64 on Monday. The firm’s 50-day moving average is $165.98 and its two-hundred day moving average is $150.46. Neurocrine Biosciences, Inc. has a 12 month low of $122.14 and a 12 month high of $186.12. The company has a market capitalization of $15.82 billion, a PE ratio of 22.82, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38.

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported $2.85 earnings per share for the quarter, beating the consensus estimate of $1.65 by $1.20. The business had revenue of $959.00 million during the quarter, compared to analysts’ expectations of $891.16 million. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The business’s revenue for the quarter was up 39.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.65 EPS. Sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 7.25 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on NBIX. Wells Fargo & Company boosted their price target on Neurocrine Biosciences from $175.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. TD Cowen raised their price objective on Neurocrine Biosciences from $200.00 to $220.00 and gave the company a “buy” rating in a report on Friday, July 31st. Citigroup lifted their target price on shares of Neurocrine Biosciences from $249.00 to $253.00 and gave the stock a “buy” rating in a research note on Thursday. Wall Street Zen lowered shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a report on Sunday, August 9th. Finally, Sanford C. Bernstein initiated coverage on shares of Neurocrine Biosciences in a research report on Friday, May 22nd. They issued an “outperform” rating and a $221.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $201.05.

Check Out Our Latest Stock Report on Neurocrine Biosciences

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Leslie Norwalk sold 1,250 shares of the firm’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $182.01, for a total transaction of $227,512.50. Following the completion of the sale, the director owned 1,588 shares of the company’s stock, valued at $289,031.88. This trade represents a 44.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Darin Lippoldt sold 10,000 shares of Neurocrine Biosciences stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $179.60, for a total value of $1,796,000.00. Following the completion of the sale, the insider owned 54,729 shares in the company, valued at $9,829,328.40. This represents a 15.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 40,188 shares of company stock worth $7,118,633. Insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Profile

(Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.